生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | ATR/ATM kinases can phosphorylate a broad and overlapping catalogue of several thousand substrates in DNA damage signaling. The kinase activity of ATR, activated by single-stranded DNA (ssDNA) coated with replication protein A (RPA), is increased at damaged replication forks and resected DNA double-strand breaks (DSBs). VE-821 is a potent and selective ATR inhibitor with Ki value of 13nM. Pre-treatment with 10μM inhibited the H2AX phosphorylation at an early time point after exposure to the S phase poisons cisplatin and gemcitabine, but not the double-strand breaks inducers etoposide and ionizing radiation in HFL1 cells, suggesting the selective inhibition on ATR by VE-821. It showed strong synergy with genotoxic agents from multiple classes, most marked with cisplatin and carboplatin, in HCT116 cancer cells, but not in normal cell lines. In addition, cisplatin and VE-821 clearly acted synergistically in the ATM-null cells but not in the normal cells, indicating the reliance on ATR for survival from DNA damage in cancer cells with defects in ATM signaling[1]. | ||
作用机制 | VE-821 is a potent ATP-competitive inhibitor of ATR.[1] |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
CAL72 | Growth Inhibition Assay | IC50~0.8 μM | 25593184 | ||
HCT-116 p53-/- | 1/3/10 μM | Cytotoxicity Assay | 1 h | potentiates the cytotoxicity of both camptothecin and LMP-400 | 25269479 |
HCT-116 p53+/+ | 1/3/10 μM | Cytotoxicity Assay | 1 h | potentiates the cytotoxicity of both camptothecin and LMP-400 | 25269479 |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.71mL 0.54mL 0.27mL |
13.57mL 2.71mL 1.36mL |
27.14mL 5.43mL 2.71mL |
参考文献 |
---|